In vitro-analysis of sorafenib as a radiosensitizing agent in epithelial cancer

Annette Affolter, Johanna Schneider, Wolf J. Mann & Jürgen Brieger
Background: Tumours of epithelial origin frequently develop resistance towards irradiation. We have recently shown that the ionizing radiation (IR)- activated MAPK pathway is involved in the survival of resistant neoplasms. We now examined if treatment with sorafenib, a potent multikinase inhibitor [for full text, please go to the a.m. URL]